Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)

About Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals logoSunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SNSS
  • CUSIP: 86732860
  • Web: www.sunesis.com
Capitalization:
  • Market Cap: $47.97 million
  • Outstanding Shares: 23,513,000
Average Prices:
  • 50 Day Moving Avg: $2.26
  • 200 Day Moving Avg: $3.05
  • 52 Week Range: $2.00 - $5.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.47
  • P/E Growth: -0.01
Sales & Book Value:
  • Annual Revenue: $1.96 million
  • Price / Sales: 24.47
  • Book Value: ($0.27) per share
  • Price / Book: -7.56
Profitability:
  • EBIDTA: ($34,640,000.00)
  • Net Margins: -1,472.94%
  • Return on Assets: -112.07%
Debt:
  • Current Ratio: 3.36%
  • Quick Ratio: 3.36%
Misc:
  • Average Volume: 107,891 shs.
  • Beta: 1.78
  • Short Ratio: 5.5
 

Frequently Asked Questions for Sunesis Pharmaceuticals (NASDAQ:SNSS)

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released its earnings results on Thursday, July, 27th. The company reported ($0.41) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.76) by $0.35. During the same quarter last year, the firm posted ($0.12) EPS. View Sunesis Pharmaceuticals' Earnings History.

When will Sunesis Pharmaceuticals make its next earnings announcement?

Sunesis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Sunesis Pharmaceuticals.

Where is Sunesis Pharmaceuticals' stock going? Where will Sunesis Pharmaceuticals' stock price be in 2017?

2 brokerages have issued 12 month price objectives for Sunesis Pharmaceuticals' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Sunesis Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Ratings for Sunesis Pharmaceuticals.

What are analysts saying about Sunesis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (8/24/2017)
  • 2. Cantor Fitzgerald analysts commented, "Advancing Toward SNS-062 Data. SNSS has just begun enrolling patients in a Phase Ib study for SNS-062, which could have utility in ibrutinib-treated patients that develop a common resistance mutation (C481) and exploring the compound in CLL and other B-cell malignancies. Results from escalation cohorts could occur in 2Q18 (possibly ASCO, AACR), which could present a revaluation opportunity for the shares." (7/27/2017)

Who are some of Sunesis Pharmaceuticals' key competitors?

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the folowing people:

  • Daniel N. Swisher Jr., President, Chief Executive Officer, Director
  • Adam R. Craig M.D., Ph.D., Executive Vice President - Development, Chief Medical Officer
  • James W. Young Ph.D., Non-Executive Independent Chairman of the Board
  • Stephen B. Ketchum Ph.D., Director
  • Geoffrey M. Parker, Director
  • Steve R Carchedi, Independent Director
  • Matthew K. Fust, Independent Director

Who owns Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BALYASNY ASSET MANAGEMENT LLC (9.32%), Balyasny Asset Management LLC (8.51%), NEA Management Company LLC (6.05%), Palo Alto Investors LLC (4.94%), DAFNA Capital Management LLC (3.62%) and Vanguard Group Inc. (2.58%). Company insiders that own Sunesis Pharmaceuticals stock include Dayton Misfeldt and Geoffrey M Parker. View Institutional Ownership Trends for Sunesis Pharmaceuticals.

Who sold Sunesis Pharmaceuticals stock? Who is selling Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC. View Insider Buying and Selling for Sunesis Pharmaceuticals.

Who bought Sunesis Pharmaceuticals stock? Who is buying Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Virtu KCG Holdings LLC, Sphera Funds Management LTD., Vanguard Group Inc. and Wells Fargo & Company MN. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Dayton Misfeldt and Geoffrey M Parker. View Insider Buying and Selling for Sunesis Pharmaceuticals.

How do I buy Sunesis Pharmaceuticals stock?

Shares of Sunesis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of Sunesis Pharmaceuticals stock can currently be purchased for approximately $2.04.


MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sunesis Pharmaceuticals (NASDAQ:SNSS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $3.00 (47.06% upside)

Analysts' Ratings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Cantor FitzgeraldReiterated RatingHold$3.00LowView Rating Details
11/3/2016Cowen and CompanyReiterated RatingHoldN/AView Rating Details
7/29/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Earnings by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Earnings History by Quarter for Sunesis Pharmaceuticals (NASDAQ SNSS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.41)N/AView Earnings Details
7/27/2017Q2 2017($0.76)($0.41)$2.40 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.83)($0.47)$1.57 million$0.67 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.43)($0.44)$0.60 million$0.68 millionViewListenView Earnings Details
11/3/2016Q316($0.71)($0.62)$0.60 million$0.60 millionViewN/AView Earnings Details
7/29/2016Q216($0.10)($0.12)$0.70 million$0.60 millionViewListenView Earnings Details
5/5/2016Q116($0.12)($0.12)$0.77 million$0.64 millionViewListenView Earnings Details
3/10/2016Q415($0.14)($0.15)$0.84 million$0.67 millionViewListenView Earnings Details
11/5/2015Q315($0.12)($0.09)$1.09 million$0.68 millionViewListenView Earnings Details
7/30/2015Q215($0.13)($0.15)$1.21 million$0.85 millionViewN/AView Earnings Details
5/5/2015Q115($0.16)($0.13)$1.14 million$0.90 millionViewListenView Earnings Details
3/12/2015Q414($0.20)($0.02)$1.17 million$0.90 millionViewListenView Earnings Details
11/10/2014Q314($0.17)($0.25)$1.97 million$0.85 millionViewListenView Earnings Details
8/5/2014Q214($0.17)($0.20)$1.32 million$2.00 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.26)$1.32 million$2.00 millionViewListenView Earnings Details
3/6/2014Q413($0.20)($0.15)$1.37 million$2.00 millionViewListenView Earnings Details
11/12/2013Q313($0.20)($0.16)$1.44 million$1.99 millionViewListenView Earnings Details
7/29/2013Q2 2013($0.21)$0.18$1.22 million$1.99 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.20)($0.23)$0.75 million$1.99 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.19)($0.20)$0.32 million$1.99 millionViewListenView Earnings Details
11/8/2012Q312($0.11)($0.37)$4.17 million$0.26 millionViewN/AView Earnings Details
8/9/2012($0.20)($0.20)ViewN/AView Earnings Details
5/15/2012($0.18)($0.30)ViewN/AView Earnings Details
11/14/2011($0.18)($0.11)ViewN/AView Earnings Details
8/11/2011($0.15)($0.18)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Current Year EPS Consensus Estimate: $-1.61 EPS
Next Year EPS Consensus Estimate: $-1.39 EPS

Dividends

Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Insider Ownership Percentage: 10.21%
Institutional Ownership Percentage: 57.54%
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Geoffrey M ParkerDirectorBuy3,740$3.87$14,473.80View SEC Filing  
5/26/2016Geoffrey M ParkerDirectorBuy9,500$0.47$4,465.00View SEC Filing  
5/25/2016Geoffrey M ParkerDirectorBuy52,505$0.47$24,677.35View SEC Filing  
12/21/2015Dayton MisfeldtDirectorBuy1,750,000$0.84$1,470,000.00View SEC Filing  
8/25/2015Daniel N Swisher JrCEOBuy12,216$1.01$12,338.16View SEC Filing  
8/24/2015Daniel N Swisher JrCEOBuy12,784$1.01$12,911.84View SEC Filing  
8/29/2014Forest BaskettMajor ShareholderSell266,700$7.97$2,125,599.00View SEC Filing  
8/28/2014Bay City Capital LlcMajor ShareholderSell300,700$7.98$2,399,586.00View SEC Filing  
8/28/2014Dayton MisfeldtDirectorSell200,000$7.89$1,578,000.00View SEC Filing  
8/27/2014Adam R CraigCMOSell2,554$8.00$20,432.00View SEC Filing  
8/27/2014Daniel N Swisher JrCEOSell5,000$8.00$40,000.00View SEC Filing  
8/27/2014Dayton MisfeldtDirectorSell100,700$8.16$821,712.00View SEC Filing  
8/27/2014Eric BjerkholtCFOSell10,000$8.00$80,000.00View SEC Filing  
8/27/2014Krishna Kittu KolluriMajor ShareholderSell108,300$8.17$884,811.00View SEC Filing  
8/12/2014Dayton MisfeldtDirectorSell743,700$6.64$4,938,168.00View SEC Filing  
8/12/2014Equity Opportunities Fu GrowthMajor ShareholderSell710,540$6.63$4,710,880.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Latest Headlines for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Source:
DateHeadline
seekingalpha.com logoSunesis Pharmaceuticals (SNSS) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
seekingalpha.com - September 9 at 8:41 AM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Downgraded by ValuEngine
www.americanbankingnews.com - September 2 at 2:29 PM
seekingalpha.com logoSunesis Pharmaceuticals: SNS-062 Could Be The Company's Salvation - Seeking Alpha
seekingalpha.com - August 31 at 10:17 AM
globenewswire.com logoSunesis to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - August 31 at 10:17 AM
finance.yahoo.com logoSunesis to Present at Upcoming Investor Conferences
finance.yahoo.com - August 31 at 10:17 AM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 27 at 4:22 PM
americanbankingnews.com logoFY2017 EPS Estimates for Sunesis Pharmaceuticals, Inc. Increased by Cantor Fitzgerald (SNSS)
www.americanbankingnews.com - August 3 at 9:30 AM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - August 2 at 8:32 AM
seekingalpha.com logoSunesis Pharmaceuticals' (SNSS) CEO Dan Swisher on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 1 at 4:03 PM
nasdaq.com logoSunesis Pharmaceuticals Reports Second Quarter 2017 Financial ... - Nasdaq
www.nasdaq.com - July 29 at 7:22 AM
finance.yahoo.com logoSunesis reports 2Q loss
finance.yahoo.com - July 28 at 8:09 AM
finance.yahoo.com logoEdited Transcript of SNSS earnings conference call or presentation 27-Jul-17 6:00pm GMT
finance.yahoo.com - July 28 at 8:09 AM
americanbankingnews.com logoCantor Fitzgerald Reiterates "Hold" Rating for Sunesis Pharmaceuticals, Inc. (SNSS)
www.americanbankingnews.com - July 27 at 9:43 PM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Posts Earnings Results, Beats Expectations By $0.35 EPS
www.americanbankingnews.com - July 27 at 5:20 PM
globenewswire.com logoSunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - July 27 at 7:39 AM
globenewswire.com logoSunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - July 27 at 7:39 AM
finance.yahoo.com logoSunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - July 27 at 7:39 AM
finance.yahoo.com logoSunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - July 27 at 7:39 AM
feeds.benzinga.com logoSunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights
feeds.benzinga.com - July 24 at 7:38 AM
globenewswire.com logoSunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK ... - GlobeNewswire (press release)
globenewswire.com - July 20 at 7:56 AM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:42 AM
finance.yahoo.com logoSunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies
finance.yahoo.com - July 18 at 8:48 PM
americanbankingnews.com logoSunesis Pharmaceuticals (SNSS) vs. Biohaven Pharmaceutical Holding Co (BHVN) Critical Analysis
www.americanbankingnews.com - July 17 at 9:55 AM
americanbankingnews.com logo-$0.76 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - July 6 at 7:36 AM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - June 28 at 7:30 AM
globenewswire.com logoSunesis Pharmaceuticals Added to Russell Microcap® Index - GlobeNewswire (press release)
globenewswire.com - June 27 at 8:01 PM
finance.yahoo.com logoSunesis Pharmaceuticals Added to Russell Microcap® Index
finance.yahoo.com - June 27 at 8:30 AM
streetinsider.com logoSunesis Pharmaceuticals (SNSS) Announces Presentation of ... - StreetInsider.com
www.streetinsider.com - June 24 at 6:51 AM
finance.yahoo.com logoSunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting
finance.yahoo.com - June 24 at 6:51 AM
americanbankingnews.com logo Analysts Expect Sunesis Pharmaceuticals, Inc. (SNSS) to Post -$0.76 EPS
www.americanbankingnews.com - June 12 at 8:30 AM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 20 at 5:35 AM
finance.yahoo.com logoThe Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug
finance.yahoo.com - May 19 at 10:01 AM
americanbankingnews.com logo-$0.76 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - May 15 at 8:16 PM
americanbankingnews.com logoZacks Investment Research Upgrades Sunesis Pharmaceuticals, Inc. (SNSS) to Buy
www.americanbankingnews.com - May 13 at 11:16 PM
finance.yahoo.com logoEdited Transcript of SNSS earnings conference call or presentation 8-May-17 6:00pm GMT
finance.yahoo.com - May 13 at 12:44 AM
americanbankingnews.com logoBrokers Set Expectations for Sunesis Pharmaceuticals, Inc.'s FY2017 Earnings (SNSS)
www.americanbankingnews.com - May 12 at 12:32 PM
finance.yahoo.com logoETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 9:01 PM
finance.yahoo.com logoSunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 10:44 AM
globenewswire.com logoSunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - May 9 at 7:25 PM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS
www.americanbankingnews.com - May 8 at 3:18 PM
finance.yahoo.com logoSunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - May 8 at 11:13 AM
finance.yahoo.com logoInvestor Network: Sunesis Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 11:13 AM
marketbeat.com logoSunesis reports 1Q loss
marketbeat.com - May 8 at 7:06 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 4 at 8:16 PM
businesswire.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors
www.businesswire.com - May 3 at 11:07 PM
finance.yahoo.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors
finance.yahoo.com - May 3 at 11:07 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sunesis Pharmaceuticals Inc.
finance.yahoo.com - May 3 at 6:05 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 6:05 PM
nasdaq.com logoSunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA)
www.nasdaq.com - May 3 at 10:45 AM
finance.yahoo.com logoSUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sunesis Pharmaceuticals Inc. To Contact The Firm
finance.yahoo.com - May 3 at 10:45 AM

Social

Chart

Sunesis Pharmaceuticals (SNSS) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff